More from ASCO 2023 [1] [2].
"Patients in the ENZAMET trial (n = 1125) were randomized 1:1 to arm A, the control arm consisting of TS plus a standard non-steroidal antiandrogen ([NSAA] bicalutamide, nilutamide, or flutamide), or enzalutamide at 160 mg per day plus TS in arm B. "
"The 5-year OS rates were 81% and 66% for those with low-volume mHSPC who did not receive docetaxel with enzalutamide and NSAA treatment, respectively, and 57% and 47% for those with high volume."
-Patrick
see also: urologytimes.com/view/clini...
TS=testosterone suppression
Bayer announces positive topline results for NUBEQA® (darolutamide) from Phase III trial in men with mHSPC - July 17, 2024Darolutamide & time to treatment discontinuation in nmCRPCBCR May Not Be a Strong Surrogate End Point for Prostate Cancer Survival
Observational: bone-modifying agents could improve overall survivalFDA Grants Priority Review to Olaparib for HRR-Mutant mCRPC - Targeted Oncology - January 20, 2020
